SEC Form 4 · accession 0001209191-18-011938
Skye Bioscience, Inc. · SKYE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Emerald Health Sciences Inc.
10% Owner
Period of report
Feb 16, 2018
Accepted (ET)
Feb 21, 2018 · 4:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516551
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 16, 2018 | P$0 | 15,000,000 | — | A | 39,000,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock Warrants (right to buy)F1 | $0.10 | Feb 16, 2018 | P | 20,400,000 | A | Feb 16, 2018 | Feb 16, 2023 | Common Stock | 20,400,000 | 20,400,000 | D |
Explanation of responses
- F1The reporting person purchased in a private placement 15,000,000 shares (the "Shares") of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), and a warrant (the "Warrant") to purchase 20,400,000 shares of Common Stock at an exercise price of $0.10 per share. The Shares and the Warrant were purchased as a unit at $.10 per unit.